Vitiligo

In 2010 Clinuvel commenced its vitiligo program to evaluate the use of its first-in-class drug SCENESSE® (afamelanotide 16mg) as a repigmentation therapy in adults with generalised vitiligo.

The first of these studies, CUV102, has completed, with treatment results released in December 2012. A further trial, CUV103, commenced in Singapore in 2014. Read more about the CUV103 study in the announcement here.

Clinuvel has established this webpage to serve as a portal for all information relevant to this study and vitiligo more broadly. See this document for more details on participating in Clinuvel's vitiligo program.

Vitiligo Blog Posts

In what has become something of a tradition in recent years, yet another country has used the new year to adopt further laws related to...

Read More

Vitiligo Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now